Epigenetics and human disease: translating basic biology into clinical applications
But again, there are more and more people now taking thymus and beta-4 for the purposes of tissue rejuvenation and repair and report positive effects
Is there already something in my stack that addresses this
doi: 10.3389/fimmu.2023.1190379 Summary Keywords tremelimumab, durvalumab, ipilimumab, nivolumab, immune checkpoint inhibitor, FAERS, adverse event Citation Li Z, Xie Y, Wang T, Liu Y, Tian Y and Hua Y (2025) Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab
Combining NSUN2 and FSP1 inhibitors with ferroptosis inducers and venetoclax enhances the elimination of AML cells [45]